×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TRVI – trevi therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TRVI
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/4
07:30 am
trvi
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
Low
Report
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
11/21
05:31 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) was upgraded by analysts at B. Riley to a "strong-buy" rating.
Medium
Report
Trevi Therapeutics (NASDAQ:TRVI) was upgraded by analysts at B. Riley to a "strong-buy" rating.
11/19
06:02 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Medium
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
11/17
08:45 am
trvi
Trevi Therapeutics: Big Cough Data, Bigger Execution Risk [Seeking Alpha]
Low
Report
Trevi Therapeutics: Big Cough Data, Bigger Execution Risk [Seeking Alpha]
11/15
07:05 pm
trvi
How Trevi Therapeutics' (TRVI) Phase 3 Progress and Fresh Funding May Influence Investor Expectations [Yahoo! Finance]
Low
Report
How Trevi Therapeutics' (TRVI) Phase 3 Progress and Fresh Funding May Influence Investor Expectations [Yahoo! Finance]
11/15
04:40 am
trvi
Trevi Therapeutics (TRVI): Assessing Valuation After Clinical Program Advances and Cash Runway Extension [Yahoo! Finance]
Low
Report
Trevi Therapeutics (TRVI): Assessing Valuation After Clinical Program Advances and Cash Runway Extension [Yahoo! Finance]
11/14
04:18 pm
trvi
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $19.00 price target on the stock.
Low
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $19.00 price target on the stock.
11/14
09:14 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Low
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/3
04:17 pm
trvi
Form 4 Trevi Therapeutics, Inc. For: Dec 02 Filed by: Galletta Christopher
Low
Report
Form 4 Trevi Therapeutics, Inc. For: Dec 02 Filed by: Galletta Christopher
11/14
04:58 pm
trvi
Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Low
Report
Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: VIKING GLOBAL INVESTORS LP
11/14
04:35 pm
trvi
Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: Frazier Life Sciences Public Fund, L.P.
Low
Report
Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: Frazier Life Sciences Public Fund, L.P.
10/17
06:25 pm
trvi
Form SCHEDULE 13G Trevi Therapeutics, Inc. Filed by: BlackRock, Inc.
Low
Report
Form SCHEDULE 13G Trevi Therapeutics, Inc. Filed by: BlackRock, Inc.
10/7
04:27 pm
trvi
Form 144 Trevi Therapeutics, Inc. Filed by: Delfini Lisa
Low
Report
Form 144 Trevi Therapeutics, Inc. Filed by: Delfini Lisa
10/3
05:09 pm
trvi
Form 144 Trevi Therapeutics, Inc. Filed by: Delfini Lisa
Medium
Report
Form 144 Trevi Therapeutics, Inc. Filed by: Delfini Lisa
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/31
Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.50 price target on the stock.
67.9%
3/16 TREVI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS AND CORPORATE UPDATE 48.3%
6/18 Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference 12.7%
5/13 Form 3 Trevi Therapeutics, Inc. For: May 07 Filed by: OSHEA WILLIAM J 11.5%
3/16 Trevi Therapeutics up 57% on advancement of key programs [Seeking Alpha] 10.3%
4/13 Form 4 Trevi Therapeutics, Inc. For: Apr 03 Filed by: Behbahani Ali 9.9%
2/25 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 8.6%
1/15 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 7.9%
11/14 Form 8-K Trevi Therapeutics, Inc. For: Nov 14 7.9%
8/21 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 7.6%
3/16 TREVI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS AND CORPORATE UPDATE 48.3%
6/18 Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference 12.7%
5/13 Form 3 Trevi Therapeutics, Inc. For: May 07 Filed by: OSHEA WILLIAM J 11.5%
3/16 Trevi Therapeutics up 57% on advancement of key programs [Seeking Alpha] 10.3%
4/13 Form 4 Trevi Therapeutics, Inc. For: Apr 03 Filed by: Behbahani Ali 9.9%
2/25 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 8.6%
1/15 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 7.9%
11/14 Form 8-K Trevi Therapeutics, Inc. For: Nov 14 7.9%
8/21 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 7.6%
TOP News Decliners
5/7
Form S-1/A Trevi Therapeutics, Inc.
-16.9%
10/10 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -9.8%
3/11 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.8%
8/12 Trevi Therapeutics Announces Second Quarter 2019 Financial Results and Recent Business Developments -7.1%
1/31 Form SC 13G Trevi Therapeutics, Inc. Filed by: Lundbeckfond Invest A/S -6.2%
2/13 Form SC 13G Trevi Therapeutics, Inc. Filed by: TPG Group Holdings (SBS) Advisors, Inc. -6.2%
9/19 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -4.9%
2/20 Trevi Therapeutics to Present at SVB Leerink Healthcare Conference -4.0%
7/2 Form 8-K Trevi Therapeutics, Inc. For: Jun 28 -4.0%
6/25 Trevi Therapeutics (TRVI) Investor Presentation - Slideshow [Seeking Alpha] -3.8%
10/10 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -9.8%
3/11 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.8%
8/12 Trevi Therapeutics Announces Second Quarter 2019 Financial Results and Recent Business Developments -7.1%
1/31 Form SC 13G Trevi Therapeutics, Inc. Filed by: Lundbeckfond Invest A/S -6.2%
2/13 Form SC 13G Trevi Therapeutics, Inc. Filed by: TPG Group Holdings (SBS) Advisors, Inc. -6.2%
9/19 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -4.9%
2/20 Trevi Therapeutics to Present at SVB Leerink Healthcare Conference -4.0%
7/2 Form 8-K Trevi Therapeutics, Inc. For: Jun 28 -4.0%
6/25 Trevi Therapeutics (TRVI) Investor Presentation - Slideshow [Seeking Alpha] -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: